IO Biotech presents pre-clinical data on IO112, IO170

IO Biotech (IOBT) announced new pre-clinical data for IO Biotech’s next vaccine candidate, IO112, and additional candidate, IO170, will be presented at the Society for Immunotherapy of Cancer’s 40th Annual Meeting, SITC 2025, in Maryland on November 5-9, 2025. Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages; Pre-clinical data for IO Biotech’s additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor-beta, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasis